Myeloma Paper of the Day, July 20th, Suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Updated follow-up of DREAMM-7 study shows continued superiority of BVd vs. DVd in median OS (NR vs. 41.0 months), PFS2 (NR vs. 33.4 months), MRD-negativity (25% vs. 10%), and duration of response (40.8 vs. 17.8 months).”
Title: Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
Authors: Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Roman Hájek, Kihyun Kim, Sebastian Grosicki, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Gracia Aparecida Martinez, Anna Sureda Balarí, Irwindeep Sandhu, Claudio Cerchione, Peter Ganly, Meletios A Dimopoulos, Chengcheng Fu, Mamta Garg, Al-Ola Abdallah, Moshe E Gatt, Albert Oriol Rocafiguera, Michele Cavo, Robert Rifkin, Tomoaki Fujisaki, Michał Mielnik, Joseph Ficek, Alejandro Mantero, Nick Pirooz, Sybil Varghese, Joe Lee, Astrid McKeown, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy-Ghanta, Pralay Mukhopadhyay, Jacqueline Nielsen, Joanna Opalinska, María-Victoria Mateos.
You can read the Full Article in The Lancet Oncology.
You can find more posts featuring Robert Orlowski in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023